This review examines how three distinct types of inflammation (and their key cellular and soluble mediators) collaborate to drive progression of idiopathic pulmonary fibrosis (IPF), focusing on the multicellular fibrotic niche rather than isolated cytokines or immune cells.
The authors argue that IPF progression is regulated by spatially and kinetically overlapping inflammatory types acting in concert — including epithelial dysfunction, peripheral immune cell infiltration, fibroblast/immune cell differentiation, and extracellular matrix remodeling — rather than a single dominant inflammatory program.
As a narrative review, no original data are presented and conclusions reflect the authors' synthesis of existing literature, which may introduce selection bias. The mechanistic overlap between inflammatory types in IPF is largely inferred from experimental models and may not fully translate to human disease.
Current IPF therapies only slow decline; this review highlights that targeting multiple overlapping inflammatory pathways simultaneously — rather than single cytokines — may be needed to achieve meaningful disease modification. Clinicians should watch for emerging combination or multi-target therapeutic strategies.
Explore related topics